Fig. 4

Discrimination performance of six Aβ prediction models overall and in subsamples following the AUR criteria. The MEMENTO Cohort, France, 2011–2014. Model 1: demographic and cognitive predictors, Model 2: Model 1 and ApoE4 status, Model 3: Model 1 and blood biomarkers, Model 4: Model 1 and MRI, Model 5: Model 1, ApoE4 status, and blood biomarkers, Model 6: Model 1, ApoE4 status, blood biomarkers, and MRI. AUC: area under the curve, AUR: Appropriate Use Recommendations, SCD: subjective cognitive decline, ε4 homozygous: homozygous for ApoE ε4. AUR population for lecanemab: population without SCD participants, without anticoagulant treatment, without siderosis, without severe subcortical hyperintensities consistent with a Fazekas score of 3, and with fewer than five cerebral microbleeds. Total population: population used to develop the predictive algorithm